MB49 Murine Bladder Carcinoma Cell Line

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Name: MB49 Murine Bladder Carcinoma Cell Line
• Alternate name: MB49, MB-49, MB49 Mouse Bladder Carcinoma Cell Line
• Cancer: Genitourinary cancer
• Cancers detailed: Bladder carcinoma;Urinary bladder neoplasms
• Research fields: Cancer
• Tool sub type: Primary
• Organism: Mouse
• Gender: Male
• Tissue: Bladder
• Disease: Cancer
• Morphology: A spindle-like epithelial morphology, or rounded
• Growth properties: The cells do not form a 100% confluent monolayer but at 70% confluence tend to detach in small clumps that float in the media. About 10-20% of the cells will be attached with a spindle-like epithelial morphology, the remainder will appear rounded
• Model: Tumourigenic line
• Model description: The cells transplanted into syngeneic mice were shown to generate carcinomas
• Crispr: No
• Conditional: No
• Description: The MB49 tumor model is a urothelial carcinoma cell line derived from an adult C57BL/ICRF-a(t) mouse bladder epithelium transformed by chemical carcinogen in culture. It is one of the most-established tumour cell line from mouse (mus musculus) to study human bladder cancer, widely used by scientists for more than 45 years after its original publication by Cancer Research UK researcher - Leonard Franks. MB49 cell line can be used both as an in vitro and in vivo murine model for bladder cancer, thanks to its clinically relevant metastatic potential. MB49 cells also shares pivotal tumour characteristics with human bladder cancer. MB49 cell line key features: (1) Rapidly generates tumours with subcutaneous or orthotopic injections into syngeneic mice (Summerhayes et al. 1979; Kasman et al. 2013). (2) Recapitulates key features of sex differences in bladder tumour growth (White-Gilbertson S, et al. 2016). (3) Loss of the Y-chromosome and expression of male-specific antigens, a frequent feature observed in human bladder cancer (Fabris et al. 2012). (4) Dose-dependent enhanced proliferation to dihydrotestosterone and lack of proliferation to human chorionic gonadotrophin (White-Gilbertson S, et al. 2016). (5) Responsiveness to immune checkpoint inhibitors (Vandeveer et al. 2016) and other agents undergoing clinical investigation (Shingo et al. 2022), making it ideal for testing novel treatment combinations. (6) Model to explore immunogene therapy, such as adenoviral vectors (Loskog et al. 2005). Further accelerate bladder cancer research, with our luminescent derivative of MB49, MB49-luc Cell Line (Cat. #: 161579). The bioluminescence can be detected by in vivo imaging and offers a readout for tumour take, growth and reduction.
• Application: In vitro and in vivo model of bladder cancer; Metastatic urothelial carcinoma research
• Production details: Derived from adult C57BL/Icrf-a’ mouse bladder epithelial cells via single 24 h treatment with a chemical carcinogen on the second day of primary culture
• Biosafety level: 1
• Cellosaurus id: CVCL_7076

Applications

• Application: In vitro and in vivo model of bladder cancer; Metastatic urothelial carcinoma research
• Application notes: The loss of Y chromosome and lack of expression of male specific antigens is a frequent early event within bladder cancer, and thus is an appropriate and effective model system. MB49 cell line displays little to no MHC class I and II molecules but MHC class II antigens are produced when stimulated with interferon. Implanted long term MB49 cells were subcutaneously injected into mice, with the primary tumours resected, mechanically disrupted and trypsin digested to obtain single cells, most of which were adherent but a small population of spheroidal 3D structures in culture. These are likely stem like, basal and highly metastatic, which is ideal for researching metastatic urothelial carcinoma. Immortalisation process: 7,12-dimethylbenz[a]anthracene on day 2 of culture.

Handling

• Format: Frozen
• Growth medium: DMEM Complete Medium or in DMEM-High Glucose with 10% FBS and 1X Penicillin/Streptomycin (optional)
• Temperature: 37° C
• Atmosphere: 5%CO2
• Unit size: 1x10^6 cells / vial
• Shipping conditions: Dry ice
• Storage medium: Cells can be cryopreserved in growth medium with 10% DMSO using a Nalgene slow freeze Mr.Frosty container.
• Storage conditions: Liquid Nitrogen
• Subculture routine: Split sub-confluent cultures (80-85%) 1:6 to 1:10 using Accutase or trypsin-EDTA solution. Cells are cultured at 37°C, in a humidified incubator with 5% CO2.
• Cultured in antibiotics: Penicillin/Streptomycin (optional)
• Mycoplasma free: Yes

Related Tools

• Related tools: MB49-luc Cell Line

References

• Albertó et al. 2019. Oncol Lett. 17(3):3141-3150. PMID: 30867744.
• Plote et al. 2019. Oncoimmunology. 8(5):e1577125. PMID: 31069136.
• Shi et al. 2019. Onco Targets Ther. 12:4403-4413. PMID: 31239709.
• White-Gilbertson et al. 2016. Bladder (San Franc). 3(1). PMID: 26998503.
• Kasman et al. 2013. J Vis Exp. (82):50181. PMID: 24326612.
• Zhu et al. 2013. BMC Urol. 13:57. PMID: 24188098.
• Fabris et al. 2012. Cancer Genet. 205(4):168-176. PMID: 22559978.
• Chen et al. 2009. J Urol. 182(6):2932-2937. PMID: 19853870.
• Loskog et al. 2005. Lab Anim. 39(4):384-393. PMID: 16197705.
• Brocks et al. 2005. J Urol. 174(3):1115-1118. PMID: 16094076.
• Günther et al. 1999. Cancer Res. 59(12):2834-2837. PMID: 10383142.
• Summerhayes et al. 1979. J Natl Cancer Inst. 62(4):1017-1023. PMID: 107359.